# Contents

## OUR FUNDAMENTALS

- Editorial  
  p. 02
- Servier, an innovative and committed health care company  
  p. 03
- Interview with the Executive Vice-President Human Resources  
  p. 04
- Our approach to CSR  
  p. 05
- CSR integrated into the strategy  
  p. 06

## OUR COMMITMENTS

- A Company Committed to Health Care  
  p. 08
- Caring About People  
  p. 12
- Focused on Our Business Practices  
  p. 16
- Aiming for a Positive Footprint  
  p. 20
The long-term vision of our Group and our independence give even more meaning to our Corporate Social Responsibility.”

At Servier, we work with passion for therapeutic progress for the benefit of patients every day. This is our vocation.

We fully embrace our social and environmental responsibility for the impact of our activities on public health, employment, the economy, social dynamics, and ecological balance.

Our caring for people and for the environment is rooted in our values. Our ethics, supported by our policy of compliance and by our Corporate Social Responsibility (CSR), are fostered by the open and transparent dialogue we have with all stakeholders and by the engagement of all employees.

Servier is an international pharmaceutical company governed by a non-profit foundation, which guarantees our independence and allows us to embed our actions in a long-term vision.

We promote access to quality health care for the greatest number of patients and contribute to the ecosystems we operate in, so as to transmit a more sustainable world to future generations. This is the meaning of our collective engagement at the heart of our corporate strategy.
Servier, an innovative and committed health care company

Servier is an international pharmaceutical company governed by a nonprofit foundation. With its head office in France, Servier has a strong international presence in 149 countries and a revenue of 4.2 billion euros (2018). Servier reinvests 25% of its total revenue (excluding generic drugs) in research and development and uses all its profits for its development.

22,000
EMPLOYEES
149
COUNTRIES
66 SUBSIDIARIES
100M
PATIENTS TREATED EACH DAY WORLDWIDE
33
DRUG CANDIDATES AND 33 RESEARCH PROGRAMS*

5 therapeutic areas
Cardiovascular diseases, diabetes, cancers, immune inflammatory diseases, neuropsychiatric diseases.

Wide-ranging health services
Our drugs from Servier R&D cover five therapeutic areas. In addition, we make quality generic drugs widely available and also offer e-health solutions, including through WeHealth Digital Medicine.

Our vocation
Committed to therapeutic progress to serve patient needs.

Our values
Care
Dare to innovate
Commit to succeed
Grow by sharing

Our vision
Through our actions, we contribute to transmit to future generations a world that can ensure access to quality health care for all.

*As of January 31, 2019
What is the role of CSR at Servier?
First and foremost this is a question of conviction, rooted in the culture of the Group. Built upon a sustainable economic model, since its creation the Group has embraced social and environmental concerns and the numerous challenges of CSR. And we practice this responsibility in all relationships with our stakeholders.

How is your CSR approach structured today?
It is a voluntary, collaborative, and company-wide action. We structure our approach so as to engage in a process of continuous improvement, based on a program of worldwide actions in line with the challenges of the company. Our aim is to pursue an ever more transparent and meaningful approach, through openness and co-construction with our partners and by promoting the sharing of good practices at all levels of the Group.

How does CSR contribute to the Group’s performance?
Our CSR policy helps consolidate links with our stakeholders, gives value to the impact of our activities, and heightens our attractiveness. We see CSR as essential to our company’s performance, based on three dimensions: therapeutic, through innovation for the patient; social, through our attention to employees, to society and through ethics; and economic, thanks to our governance and to an efficient management of the company. These three dimensions guarantee our sustainability and our independence.
Our approach to CSR

The pharmaceutical sector contributes to the health system and is thus at the center of a large number of stakeholder expectations, notably concerning economic, social, and environmental issues.

In this context, the Group has put in place a Corporate Social Responsibility (CSR) strategy, the outcome of a consultation process with our stakeholders and a strong commitment.

Following the ISO 26000 guidelines and their seven main questions, in 2016 we assessed CSR stakes considered relevant to our business and our Group. Based on interviews with fifty internal and external stakeholders, this relevance analysis enabled us to identify our major CSR challenges.

Using this robust and participatory methodology, we have defined 4 main CSR commitments and 17 priority stakes, out of 37 initially evaluated, in line with our values and our corporate strategy. This work is the basis of our CSR roadmap, which is continuously enriched through constant improvement, by capitalizing on existing best practices and on action plans devised jointly with each department involved in new projects.

**FOCUS ON 17 PRIORITY STAKES**

We are addressing stakes in our four main strategic areas
• Caring about people • A company committed to health care • Focused on our business practices • Aiming for a positive footprint
We are convinced that CSR creates value for the Group and its stakeholders. We have put in place a dedicated governance so that CSR permeates all levels of the company, from general management to the 22,000 employees, via all business activities and their processes.

In 2016, we created a CSR Department whose mission is to deploy the CSR strategy at all of our sites, in all departments, and to all employees. The department also monitors the progress of action plans, achievement of goals, and extra-financial indicators predefined with the Group’s departments.

To implement its roadmap and ensure its consistency with the Group’s objectives, the department works with several bodies:

**CSR GOVERNANCE**

**EXECUTIVE COMMITTEE**
- Validates the CSR strategy.

**EXECUTIVE VICE-PRESIDENT HUMAN RESOURCES**
- Contributes to local deployment by including the CSR strategy in activities.
- Extra-financial reporting and communication.

**GROUP CSR COMMITTEE**
- Participates in defining CSR guidance.

**CSR OPERATIONS COMMITTEE**
- Participates in the CSR action plan and key projects.
- Contributes to including CSR in functions.
- Proposes CSR actions based on feedback and competitive intelligence.

**CSR DEPARTMENT**
- Proposes a strategy, commitments, and a CSR action plan.
- Evaluates the Group’s CSR achievements and actions and its performance.
- Defines and coordinates deployment, communications, CSR reporting.

**CSR GOVERNANCE**

**CSR NETWORK**
- Contributes to local deployment by including the CSR strategy in activities.
- Extra-financial reporting and communication.

**Performance leverage**

Corporate Social Responsibility represents a real performance driver. CSR has therefore been included in the key performance indicators reported regularly to the Executive Committee. At the same time, we continue to integrate CSR into the strategic plans of all the Group’s departments and are developing indicators according to Global Reporting Initiative standards.
Our 4 Commitments and 17 Priority Stakes

A company committed to health care

- Product safety and quality
- Anti-counterfeiting
- Ecodesign
- Global approach to health care

Caring about people

- Health and safety at work
- Employee wellbeing
- Diversity and equal opportunities
- Managerial practices

Focused on our business practices

- Business ethics
- Responsible purchasing
- Ethics and transparency of clinical trials
- Responsible marketing and promotion
- Stakeholder engagement

Aiming for a positive footprint

- Access to health care
- Local development and community engagement
- Climate change and responsible use of resources
- Effluent and waste management

Perspectives

Through annual reporting, Servier openly shares with all its stakeholders the Group’s good practices, projects, and the progress of its CSR strategy. The Group aims to be a signatory to the United Nations Global Compact and to define in 2019/2020 an action plan targeting sustainable development goals, as defined by the United Nations.
A COMPANY COMMITTED TO HEALTH CARE

In the countries where we operate, we are committed to making quality therapeutic solutions accessible to as many people as possible. This is reflected in the very high level of quality and safety of our medicines and in the special attention we pay to the fight against falsified and counterfeit drugs. In the framework of a global approach to health care, we also offer patients services and solutions designed to increase the efficacy of their treatment and to improve their everyday quality of life.
Complete control of drug production

One of our strengths is having complete control of all stages of the life cycle of the drug, from research to distribution. Most of our drugs are manufactured at the Group’s 16 production sites, which meet the highest regulatory requirements, thereby guaranteeing their quality. To fight drug counterfeiting, which is on the increase, notably via internet sales, we have deployed in 45 countries a program for the serialization, aggregation, and traceability of salable units. This strategy offers an opportunity to innovate throughout the life cycle of a drug, through EcoDesign by Servier (see overleaf). Our commitment to quality is also expressed through the daily needs of patients, via our patient-centered approach and our eHealth service, WeHealth Digital Medicine.

43 training sessions were run by Servier in 2018, in 15 countries, to raise awareness among 2,000 external stakeholders (customs officers, policemen and women, health authorities, etc.) of the challenge posed by counterfeit Servier medicines.

50 projects are undergoing feasibility analysis in the framework of our eHealth service, WeHealth Digital Medicine.

“Within the framework of our approach to Patient Centricity, we are committed to implementing an open and interactive relationship with patients. It is vital in this approach that we take note of patients’ experiences and listen to their needs. By taking into account their expertise, we can build both with and for them the solutions most relevant to their lives, to their family and loved ones and also to medical research. This collaboration naturally includes patient groups, which are inseparable from a patient-oriented strategy.”
**Green chemistry in the spotlight**

The Servier chemical production site ORIL Industrie (Bolbec, France) received the 2017 UIC Normandy Responsible Care Award for its guide to ecofriendly solvent choices.

“Our approach, which is underpinned by a multidisciplinary working group, has been particularly remarkable, since we have designed this guide with our activity fully in mind. The Sustainable Chemistry group will reassess the environmental impact of our processes (Green Score).”

Alexandre Le Flohic, COORDINATOR OF SUSTAINABLE CHEMISTRY AT ORIL INDUSTRIE

**Helping cancer patients feel better: dietary tips and recipes from Biogaran**

Cancer treatments often result in loss of appetite, nausea, difficulty chewing, etc. They can even lead to malnutrition. To improve the quality of life of cancer patients, Biogaran has published “Mieux dans mon assiette avec le cancer,” a book that offers tips and recipes from a cook and a dietitian. It is available free of charge in pharmacies in France.

**Servier prioritizes the fight against counterfeit drugs**

“Counterfeit drugs are a major public health danger. Their first victim is the patient, which is why the fight against counterfeit drugs is a priority for Servier. This fight calls for all those involved to be coordinated, both internally, where all the departments involved work cross-functionally, and externally, through greater cooperation with the customs authorities, police, and health authorities, and with other pharmaceutical firms, in particular as part of French and international organizations such as G5, EFPIA,* and PSI**.”

Catherine Boudot, DIRECTOR OF THE DEPARTMENT OF TRADEMARKS AND THE FIGHT AGAINST FALSIFICATION

* European Federation of Pharmaceutical Industries and Associations
** Pharmaceutical Security Institute

**Mediator**

Some patients undeniably suffered adverse effects with Mediator. Each day, we commit to paying special attention to how we manage each of the situations experienced by these patients, with respect to individuals and their relatives. The Servier Group has committed to compensating every victim addressed by the Oniam (Office national d’indemnisation des accidents médicaux (National Office for Compensation of Medical Accidents) panel of experts and forensic experts. As of now, the patient compensation process is almost complete. As of June 3, 2019, 3,647 patient claimants have received an offer of compensation for a total of €148.5 million, 120.5 million of which have already been paid. All information relating to patient compensation is available at www.servier.com.

**My BP Coach, a pocket health coach**

To prevent hypertension and to encourage those affected to adopt good daily habits, Servier has launched a cell phone app called My BP Coach. Experts in nutrition, sport, and relaxation give tailor-made advice (recipes, exercise, relaxation, quizzes, etc.).
Eco Design
by Servier

CONTEXT: The importance of correct drug usage, increased environmental concerns, greater attention paid to the ecological impact of pharmaceutical production... As a company committed to health care, we are acutely aware of our responsibility to the environment and to our stakeholders throughout the life cycle of the drug.

OUR RESPONSE: Our ambition is to include the principles of ecodesign in the development of our future drugs, throughout the value chain of the drug, from R&D to its disposal, notably via the choice of raw materials, its manufacture, and its use. Key to this are safe and quality therapeutic solutions which meet patient needs, in line with our patient-centered approach and environmental concerns. This global initiative will be launched in 2019 by a multidisciplinary project team and will be implemented in two phases:

- definition of the methodology, by means of a pilot project, and a Group Ecodesign reference system for our future drugs;
- progressive application to all new drugs in development, on the basis of feedback.

This project, which will promote innovation and co-construction, will also enable us to strengthen certain initiatives and to identify potential areas for improvement for existing drugs.

POINT OF VIEW

"This project, which aims to go even further in integrating environmental and social issues in the development of our future drugs, will have a structuring effect for the future. It will impact our value chain, with benefits expected for the patient, but also in terms of industrial, logistic, and environmental performance. The project will illustrate our capacity to innovate sustainably throughout the life cycle of the drug."

Vincent Minvielle
DIRECTOR GROUP CSR
Employees drive our performance and our capacity to innovate for the benefit of patients. They are also at the heart of our responsibility. We have therefore implemented a policy of safety and wellbeing and of equal opportunity in the workplace. And in parallel, we care about the development of each individual, which is why we support employees throughout their careers so they can develop their skills and evolve within the Group.
Care and support

We care about the health, safety and well-being at work of all the 22,000 employees. The Group has always held dear the development of strong social values and has been recognized for many years for implementing greater health coverage for employees in numerous countries, whatever the legislation in force. This caring for people is also characterized by the support we provide to employees throughout their careers, from recruitment to training and career development.

We are particularly attentive to the onboarding of new employees. For each new hire, we draw up a personalized program designed to facilitate learning about our business areas, but also to pass on human and practical guidance to promote career growth within the Group.

KEY FIGURES

3 industrial sites have OHSAS 18001/ISO 45001 accreditation (management system of occupational health and safety), in the framework of our safety policy.

22,000 employees, that is all the Group’s employees, were made aware of Servier’s culture of responsibility at the in-house Rise4All events held from April to December 2018. These events were designed to share the company’s key strategic orientations with employees around the world.

45% of the Group’s managers are women.

POINT OF VIEW

“Servier Russia was awarded the title of Best Employer 2018. One thousand people took part in a survey on management, quality of training, recognition at work, skills management, and employee empowerment. Results: a 90% satisfaction rate! We are delighted to have received this award, which bears witness to employees’ engagement and to their pride in belonging to our Group!”

Elena Egorova
HR MANAGER UEEA (EURASIAN ECONOMIC UNION)
HIGHLIGHTS

Safety is everyone’s concern at Arklow (Ireland)

“Safety has long been a priority at our Arklow industrial site. In 2018, we renewed our approach by launching a program called SAFE (Safety Always For Everyone). What made this program special was that we designed it collaboratively and cross-functionally, by involving 50 employees for 5 months. They were then tasked with teaching their colleagues, to enable everyone to take on board and share this safety first culture.”

Martin Wolohan, HEAD OF ENGINEERING AND EHS AND SPONSOR OF THE PROGRAM

Raising awareness of the issue of diversity

Fighting discrimination is anchored in the Group’s values, and since 2018 we have strengthened the fight by including it as one of the mandatory assessment criteria for the Group’s 22,000 employees.

Fostering managerial dialogue underpinned by our values

The annual performance reviews conducted at all our subsidiaries and sites promote open and constructive discussion between managers and their teams, and are essential for an exchange of views on the career prospects of employees. Structured around our four values, these reviews offer an excellent platform to communicate our values to all employees and strengthen ongoing dialogue.

Happy Trainees

4.05/5
This is the Happy index® given by 57.2% of the Group’s trainees and co-op students around the world, in the framework of Happy Trainees 2018. 92% of students recommended Servier as a place to do an internship, work-linked training, or a Volunteer for International Experience (VIE) program. Thanks to this result, Servier has risen to 4th in the ranking of international companies for their internship policy.

35 countries of the Group use home office to promote organizational flexibility, autonomy, and the work-life balance of employees.

1 in 2 employees at head office telework
The nonprofit organization HandiEM seeks to implement a pharmaceutical industry-wide agreement on the employment of people with disabilities. Since 2011, Servier has joined forces with HandiEM in collective projects, awareness-raising sessions, and courses on the subject of disabilities, organized jointly with employees and all stakeholders, including human resources. All these actions are supported by a voluntary policy of maintaining the employment and skills development of people with disabilities, reflecting the strong and measurable engagement of a company determined to change perceptions regarding disabilities.

Céline Grelier  
MISSION HANDICAP DIRECTOR, HANDIEM (HANDICAP ENTREPRISES DU MÉDICAMENT)
In all interactions with our stakeholders (patients, employees, partners, suppliers, public authorities, institutions, civil society), we aim to establish a reliable relationship in line with our values. We are disseminating this requirement for integrity and ethical behavior throughout the Group by means of common rules laid down in our Ethical Charter and Code of Conduct, which are applicable to all employees.
Two watchwords: ethics and transparency

Our approaches relating to CSR and compliance are at the heart of our corporate ethics. They create a framework for the prevention of corruption and conflicts of interest, and meet national (such as the Sapin 2 law in France) and international legal obligations as well as the expectations of all our stakeholders. Our action is also guided by transparency. We strive to be exemplary in terms of communication regarding our clinical trials, so as to advance medical understanding and to better support patients. In parallel, with our Medical Affairs team, which combines scientific excellence and rigor, we engage in objective and quality dialogue with the medical and scientific communities.

100% of Servier clinical trials in Europe are published on the European Union Clinical Trials Register (EUCTR) website. As of 2013, Servier, as a member of EFPIA, is committed to greater transparency of clinical trials for the benefit of patients and medical knowledge, in particular through its website https://clinicaltrials.servier.com/.

388 training courses on compliance (excluding General Data Protection Regulation) since February 2016 within the Group, involving all 22,000 employees.

“A drug is not like other consumer products. It involves increasing responsibility on the part of all those concerned. Our Group’s compliance program is therefore structuring. It is not just a question of meeting increasingly strict legal obligations. Rather, more broadly, it forms a framework of ethical behavior and responsibility for all employees worldwide.”

Marie-Christine Larcher
LEGAL AND COMPLIANCE DIRECTOR
A policy of responsible purchasing

“It seemed essential to integrate purchases, which amount to €1.46m, into the CSR strategy. A team in the Purchasing Department was created to work on CSR and on the evaluation of suppliers. Its principal aims are to be at the service of purchasers and internal clients, to roll out the roadmap for responsible purchasing, and to identify and prevent risks associated with suppliers. For this we lean heavily on the CSR strategy to structure and reinforce our actions/procedures, so as to promote good practice in the Group.”

Alexis Wlodarczyk,
DIRECTOR OF RESPONSIBLE PURCHASING

Collaborations with the medical community to benefit patients

As an example, since 2018 we have participated in the largest independent group of stakeholders in patient-centered care: the global collective platform called Patient-Focused Medicines Development (PFMD). We have also joined the public-private partnership funded by the Innovative Medicines Initiative (IMI) and the EFPIA: PARADIGM — Patients Active in Research and Dialogues for an Improved Generation of Medicines. This partnership is intended to improve the engagement of patients in the life cycle of drugs so as to improve health results.

Providing access to research data

“At Servier, we are committed to creating innovation for the benefit of patients and we conduct all phases of our clinical development programs in accordance with the highest ethical standards. In the interest of research and of the public, we share information on our studies on our website https://clinicaltrials.servier.com/, with the investigators and patients (summarized in non-technical language for the latter) and allow researchers to request access to the data generated, while respecting the protection of personal data.”

Catherine Salvadori,
PHARMACEUTICAL AFFAIRS WORLD. INTERNATIONAL AND PRE-REGISTRATION DIVISION, DIRECTOR

An exemplary compliance program by Servier China

The Group’s largest subsidiary, Servier China, has put in place a structured and ambitious compliance program. An ethics committee comprising the four members of the Compliance Department and representatives of the main activities was set up to implement a “zero tolerance” policy regarding corruption, through a risk detection and assessment program, as well as the dissemination of good practice.

A compliance award for Servier Germany

After an analysis based on 200 criteria, Servier Germany received a compliance award from AKG, a reference institution in the matter. This award recognizes the quality of the subsidiary’s interactions with health professionals and organizations.
Servier 1st class partner

CONTEXT: The quality of our relations with our partners has always been essential. By building trust, constructive dialogue, and shared responsibility, we are developing a sustainable partnership model that is in line with our values and long-term vision. This component of our corporate strategy combines observation of regulatory requirements regarding business practices and fulfilling the expectations of our stakeholders for a balanced collaboration.

OUR RESPONSE: Our partnership model involves mutual respect of economic, ethical, and responsible engagement. It is based, on the one hand, on a project for the formalization of our partnership policies and their effective implementation, through procedures/actions for global and responsible performance. On the other hand, we are pursuing the progressive integration of CSR criteria in the key steps of our purchasing process, and we are working on risk assessment regarding our suppliers. Our aim is to share and co-create with our partners and suppliers so as to promote long-term and trusting relationships. For our stakeholders, this approach will thus become a driver for innovation, competitiveness, and differentiation.

POINT OF VIEW

Servier and Simplon, a network of supportive and inclusive schools that offer free training for digital jobs, have launched an unprecedented program of open innovation. The aim is to encourage students to undertake an entrepreneurial initiative with the aim of developing innovative digital solutions to help both health professionals and patients. And in April 2018, the Servier Group gave Frédéric Sarr financial backing and expertise to help him develop an app for use in the management of depression. “Code & Care by Simplon & Servier is for us a new model of partnership with companies, combining the development of our students intrapreneurship, digital innovation, and a relationship of trust with our partner.”
Our aim is to increase our positive footprint by promoting access to quality health care for the greatest number of patients. One hundred million patients are treated every day with our brand-name and generic drugs. We aim to create economic and social value for the countries in which we operate, while limiting the ecological impact of our activities.
Sustainable local presence, creator of shared value

We provide therapeutic solutions that meet the needs of local populations, thanks to our international development, range of medicines, and tailored approach to each country in which our brand-name and generic drugs are prescribed. Our ambition is to create economic, social, and community value wherever we operate, through our activities and our engagement with local communities, while limiting our environmental impact. In France, for example, we are continuing to increase skills and highly qualified positions at our production sites at Gidy and Bolbec and at our future Servier Paris-Saclay Research Institute. In this way we are contributing to the vitality of these regions. We also believe in long-term presence, elsewhere in the world. In 2018, we celebrated 60 years in Spain, 45 in Venezuela, 40 in Canada and in Switzerland, and 25 in Vietnam and in Bulgaria.

POINT OF VIEW

“Since 2016, the Mécénat Servier Charity Fund has been structured around several areas of engagement, with a particular focus on health, but also on education and living together. Through this choice favoring our presence and links to local communities, we affirm our wish to have a significant impact on society as a whole.”

Corinne Massin
GENERAL DELEGATE
MÉCÉNAT SERVIER CHARITY FUND

KEY FIGURES

6
industrial sites and head office are accredited or undergoing ISO 14001 (environmental management system) and/or ISO 50001 (energy management system) certification.

23
nonprofit partners since the creation of the Mécénat Servier Charity Fund.

+€1M
allocated to the Mécénat Servier Charity Fund.
Mécénat Servier Charity Fund: for the public interest

#1 FINANCIAL SUPPORT

285 children have received surgery at the Cuomo Pediatric Cardiology Center in Dakar since it opened in January 2017. Servier teams helped to train Senegalese medical teams for six months in Vietnam.

#2 EMPLOYEE VOLUNTEERING

146 employees volunteered in nonprofit organizations between March 2017 and September 2018.

#3 CONGÉ SOLIDAIRE® WITH PLANÈTE URGENCE

34 employees volunteered in 2018 for two-week international solidarity missions (education of young children or adults, protection of biodiversity) in Africa, Asia, or Latin America during their vacation time.

“At the start, Mécénat Servier anticipated 5 volunteer employees for this first year of Congé Solidaire®. In fact, 34 people signed up in just one week. This means that in 2018, one in every ten people on a mission with Planète Urgence were Servier employees.”

Muriel Roy, DIRECTOR OF PARTNERSHIPS AT PLANÈTE URGENCE

Promoting access to care for patients with chronic diseases

In 2019, Servier joined the global partnership Access Accelerated, which is working to improve access to the prevention and treatment of non-communicable diseases in low- and middle-income countries. This initiative is supported by 26 international pharmaceutical companies and by the leading organizations of the pharmaceutical industry (IFPMA, EFPIA, PhRMA, Bio, and JPMA).

With this participation, the Group wishes to step up its efforts to improve access to health care around the world.
In 2019, we are conducting a first study of our socioeconomic impact in the principal countries in which we operate, with a view to measuring the contribution of our activities on employment, wealth generation, and the part of local integration of our activities. This analysis will be completed with the evaluation of the impact of projects supported by the Mécénat Servier Charity Fund. This overall assessment will then enable us to identify the levers for action to enhance our value creation in the areas in which we are present.

The fight against climate change is one of the greatest challenges in terms of sustainable development. Servier is working on a low-carbon strategy in line with the Paris COP 21 agreement (<2°C by 2030). This fight will be based notably on reducing our direct and indirect impact in terms of greenhouse gases. It will also include the supply of carbon-free energy and carbon offset.

We use the internationally recognized SBTi (Science Based Targets initiative) methodology. Our precise objectives and timetable will be defined during 2019. Numerous actions are already under way (regeneration of solvents at our chemical sites, transition from air travel to shipping for our logistic flows, reduction of energy consumption at our industrial sites and at head office, etc.), and the Group is aiming for carbon neutrality.

“Utopies has developed LOCAL FOOTPRINT®, a socioeconomic impact model intended to help organizations understand their impact on the economy and to identify levers to strengthen their links with local ecosystems, thus contributing to the development of a more local, sustainable, and resilient economy. These studies can be done at different geographic levels (urban area, department, region, country, or world) and on different subjects (products, brands, sectors, production sites, company).”